DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus--mechanism of prolonged antidiuresis.

@article{Seif1978DDAVPT,
  title={DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus--mechanism of prolonged antidiuresis.},
  author={S. Seif and T. Zenser and F. Ciarochi and B. Davis and A. Robinson},
  journal={The Journal of clinical endocrinology and metabolism},
  year={1978},
  volume={46 3},
  pages={
          381-8
        }
}
DDAVP, 1-desamino-8-D-arginine-vasopressin, is a synthetic analog of arginine vasopressin which produces prolonged antidiuresis after intranasal administration to patients with complete central diabetes insipidus. We have studied the mechanism of the prolonged antidiuretic effect by specific radioimmunossay of DDAVP in plasma of patients and by in vitro studies on the adenylate cyclase-cylic AMP system of the rat outer renal medulla. When DDAVP was administredd to patients, all responded, but… Expand
DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of lithium-induced polyuria in the rat.
  • S. Christensen
  • Chemistry, Medicine
  • Scandinavian journal of clinical and laboratory investigation
  • 1980
TLDR
The reversibility of lithium-induced impairment of renal concentrating ability caused by excessive hormonal stimulation is not immediately compatible with the recent hypothesis that lithium-polyuria may reflect irreversible structural kidney damage. Expand
Resistance of 1-deamino-[8-D-arginine]-vasopressin to in vitro degradation as compared with arginine vasopressin.
TLDR
The resistance of dDAVP to digestive enzymes, late pregnancy plasma and sodium thioglycollate might be responsible for the prolonged antidiuretic action of d DAVP in vivo. Expand
DDAVP (1-desamino-8-D-arginine vasopressin) clearance rate.
TLDR
The relatively decreased CR of DDAVP appears to account largely for the approximately 5-fold prolongation of antidiuresis of this synthetic derivative relative to AVP. Expand
1‐Deamino‐8‐D‐arginine vasopressin and urine cyclic adenosine monophosphate excretion in diabetes insipidus
TLDR
It is confirmed that DDAVP intranasally induces antidiuresis in patients with diabetes insipidus over approximately 12 hr, indicating that urinary cAMP is a poor index of antidiuretic hormone action on the distal nephron. Expand
Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man
TLDR
The bioavailability of dDAVP after gastric, duodenal and jejunal application was similar to that after swallowing a tablet in a previous study, and the bioavailability was significantly higher in the three upper GI regions in comparison to the three lower regions. Expand
Central Diabetes Insipidus in Children
TLDR
This peroral DDAVP tablet proved to be as effective as the intranasal administration of D DAVP and was preferred by the patients and constitutes one of the first examples of a peptide conserving its biological activity after gastrointestinal transport. Expand
Biological half-life and organ distribution of [3H]1-deamino-8-D-arginine-vasopressin in the rat.
The biological half-life of synthetic, radiochemically pure, biologically active [3H]1-deamino-8-D-arginine-vasopressin (dDAVP) in rats was found to be 5.33 +/- 0.28 (S.E.M.) min in the initial,Expand
Antidiuretic responses to injected desmopressin, alone and with indomethacin.
TLDR
Injected dDAVP, generally in the amount of 1 or 2 microgram, would be a valuable agent in the treatment of diabetes insipidus and that combined therapy with indomethacin is probably not warranted. Expand
Basic Pharmacology of Desmopressin
TLDR
The potent antidiuretic activity of desmopressin makes the peptide ideal for the treatment of cranial diabetes insipidus, however, it may also be used for nocturnal enuresis and as a diagnostic agent in determining renal concentrating capacity. Expand
BIOLOGICAL HALF‐LIVES AND ORGAN DISTRIBUTION OF TRITIATED 8‐LYSINE‐VASOPRESSIN AND 1‐DEAMINO‐8‐D‐ARGININE‐VASOPRESSIN IN BRATTLEBORO RATS
TLDR
The results have led to the conclusion that the accelerated elimination of vasopressin and its pathologic organ accumulation are probably not involved in the water metabolism disturbance of Brattleboro rats with hereditary diabetes insipidus. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
DDAVP in the treatment of central diabetes insipidus.
TLDR
DDAVP gives promise of becoming the standard treatment of severe central diabetes insipidus because of its increased antidiuretic activity and decreased pressor activity. Expand
Vasopressin Analogue DDAVP in Diabetes Insipidus: Clinical and Laboratory Studies
TLDR
The slow metabolic clearance of DDAVP, its absorption through the nasal mucosa, and its lack of side effects make this the ideal drug for the treatment of vasopressin-sensitive diabetes insipidus. Expand
TREATMENT OF DIABETES INSIPIDUS IN CHILDREN WITH DDAVP, A SYNTHETIC ANALOGUE OF VASOPRESSIN
TLDR
It is concluded that DDAVP is a valuable alternative in the treatment of vasopressin sensitive diabetes insipidus in children, and that it is well suited for long‐term use. Expand
Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action.
TLDR
Deamination is thus clearly the primary molecular change that endows arginine vasopressin analogues with greatly prolonged antidiuretic effects, while introducing more lipophilic side-chains in the 4-positio... Expand
Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity.
TLDR
Testing the hypothesis that the lipophilic character of the side chain on the amino acid in the 4-position plays a key role in endowing vasopressin analogs with enhanced antidiuretic specificity found that substitution of valine for glutamine did indeed enhance specificity. Expand
Synthesis and biological properties of 1-desamino-8-lysine-vasopressin.
TLDR
The synthesis and biological properties of 1-desamino-8-lysine-vasopressin demonstrated clearly that the free amino group of oxytocin is not essential for biological activity. Expand
SYNTHETIC VASOPRESSIN NASAL SPRAY IN THE TREATMENT OF DIABETES INSIPIDUS.
TLDR
The use of synthetic lysine vasopressin, lysyl-8-vasopressinsensitive diabetes insipidus, as a nasal spray has been studied and clinical response to the medication is reported here. Expand
Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma.
TLDR
The radioimmunoassay method provides a useful way of assessing AVP function in man and, when used appropriately, approximate the anticipated levels and vary in accordance with physiologic expections. Expand
Comparison of the pharmacologic properties of oxytocin and its highly potent analogue, desamino-oxytocin.
TLDR
It has been found that the free amino group is not required for manifestation of the biologic activities of oxytocin which are studied herein and increased antidiuretic and decreased pressor activities also occur upon replacement of the amino group in the 1 position of lysine-vasopressin with hydrogen. Expand
Effects of vasopressin and prostaglandin E 1 on the adenyl cyclase-cyclic 3',5'-adenosine monophosphate system of the renal medulla of the rat.
TLDR
Results in the inner medulla are consistent with the hypothesis that PGE(1) can compete with vasopressin for adenyl cyclase-binding sites, but the findings in the outer medulla suggest the situation is more complex. Expand
...
1
2
3
...